UnknownNCT05923372
Evaluation of the DALY on a Cohort of Patients With Indolent Systemic Mastocytosis
Studying Indolent systemic mastocytosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Hospital, Toulouse
- Principal Investigator
- Cristina BULAI LIVIDEANU, MDUniversity Hospital, Toulouse
- Enrollment
- 160 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2024
Study locations (1)
- Centre de Référence des Mastocytoses, Service de Dermatologie, Hôpital Larrey, CHU Toulouse, Toulouse, Haute-Garonne, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05923372 on ClinicalTrials.govOther trials for Indolent systemic mastocytosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07255638A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in GermanyBlueprint Medicines Corporation
- ACTIVE NOT RECRUITINGPHASE2NCT05186753(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic MastocytosisCogent Biosciences, Inc.
- RECRUITINGPHASE2, PHASE3NCT04910685(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic MastocytosisBlueprint Medicines Corporation
- RECRUITINGPHASE2NCT04655118Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic MastocytosisTelios Pharma, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT03731260(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic MastocytosisBlueprint Medicines Corporation